JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

Search

Eli Lilly and Co.

Chiusa

SettoreSettore sanitario

696.49 -1.99

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

694.22

Massimo

712.89

Metriche Chiave

By Trading Economics

Entrata

2.9B

5.7B

Vendite

2.8B

16B

P/E

Media del settore

45.864

35.473

EPS

6.31

Rendimento da dividendi

0.8

Margine di Profitto

36.384

Dipendenti

47,000

EBITDA

3.3B

7.5B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+31.86% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.80%

2.38%

Utili prossimi

30 ott 2025

Prossima data del Dividendo

10 set 2025

Prossima data del' Ex Dividendo

14 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-62B

629B

Apertura precedente

698.48

Chiusura precedente

696.49

Notizie sul Sentiment di mercato

By Acuity

38%

62%

136 / 372 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Eli Lilly and Co. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 ago 2025, 15:59 UTC

I principali Market Mover

Immuneering Shares Climb On Supply Agreement with Eli Lilly

7 ago 2025, 11:36 UTC

Utili

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

12 ago 2025, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8 ago 2025, 19:34 UTC

Discorsi di Mercato

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 ago 2025, 05:32 UTC

Discorsi di Mercato

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 ago 2025, 16:20 UTC

Utili

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7 ago 2025, 14:18 UTC

Discorsi di Mercato
Utili

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7 ago 2025, 13:54 UTC

Utili

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7 ago 2025, 12:12 UTC

Utili

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7 ago 2025, 11:58 UTC

Utili

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

7 ago 2025, 11:32 UTC

Utili

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 ago 2025, 11:03 UTC

Utili

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 ago 2025, 10:49 UTC

Utili

Eli Lilly 2Q Gross Margin 84.3% >LLY

7 ago 2025, 10:48 UTC

Utili

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

7 ago 2025, 10:47 UTC

Utili

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

7 ago 2025, 10:46 UTC

Utili

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

7 ago 2025, 10:46 UTC

Utili

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

7 ago 2025, 10:46 UTC

Utili

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

7 ago 2025, 10:45 UTC

Utili

Eli Lilly 2Q Net $5.66B >LLY

7 ago 2025, 10:45 UTC

Utili

Eli Lilly 2Q Rev $15.56B >LLY

7 ago 2025, 10:45 UTC

Utili

Eli Lilly Sees FY Adj EPS $21.75-Adj EPS $23.00 >LLY

7 ago 2025, 10:41 UTC

Utili

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 ago 2025, 20:34 UTC

Utili

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 ago 2025, 08:45 UTC

Utili

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

30 lug 2025, 10:38 UTC

Discorsi di Mercato

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

29 lug 2025, 17:05 UTC

Utili

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29 lug 2025, 16:55 UTC

Utili

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29 lug 2025, 13:35 UTC

Utili

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29 lug 2025, 11:39 UTC

Utili

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

25 lug 2025, 12:49 UTC

Acquisizioni, Fusioni, Takeovers

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

Confronto tra pari

Modifica del prezzo

Eli Lilly and Co. Previsione

Obiettivo di Prezzo

By TipRanks

31.86% in crescita

Previsioni per 12 mesi

Media 938.39 USD  31.86%

Alto 1,190 USD

Basso 700 USD

Basato su 22 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Eli Lilly and Co. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

22 ratings

17

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 884.54Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

136 / 372 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.